Edition:
United States

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.66USD
16 Feb 2018
Change (% chg)

$-0.11 (-0.66%)
Prev Close
$16.77
Open
$16.77
Day's High
$16.80
Day's Low
$15.84
Volume
1,246,713
Avg. Vol
109,273
52-wk High
$20.43
52-wk Low
$11.25

Latest Key Developments (Source: Significant Developments)

Athenex Files For Offering Of Up To 4.3 Million Shares
Monday, 22 Jan 2018 07:15am EST 

Jan 22 (Reuters) - Athenex Inc ::ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING.  Full Article

Athenex Announces Proposed Offering Of Common Stock
Monday, 22 Jan 2018 07:10am EST 

Jan 22 (Reuters) - Athenex Inc ::ATHENEX, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 4.30 MILLION COMMON SHARES.  Full Article

Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol
Monday, 22 Jan 2018 07:00am EST 

Jan 22 (Reuters) - Athenex Inc ::ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER.ATHENEX - ‍AMONG FIRST 12 EVALUABLE PATIENTS, 50% HAD PARTIAL RESPONSE, 50% HAD STABLE DISEASE IN TRIAL OF ORAXOL FOR TREATMENT OF BREAST CANCER​.  Full Article

Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol
Tuesday, 16 Jan 2018 08:00am EST 

Jan 16 (Reuters) - Athenex Inc ::ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL.ATHENEX INC - SECOND INTERIM ANALYSIS OF ORAXOL PHASE III CLINICAL STUDY BASED ON 180 EVALUABLE PATIENTS IS PLANNED FOR MIDDLE OF 2018.  Full Article

Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Athenex Inc ::ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS.ATHENEX INC - ACCEPTANCE OF ORAXOL IND BY CHINESE FDA ALLOWS ATHENEX TO COMMENCE A CLINICAL TRIAL PROGRAM FOR ORAXOL IN CHINA IN 2018.  Full Article

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 11:31am EST 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle
Friday, 1 Dec 2017 08:00am EST 

Athenex Inc ::ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE.ATHENEX INC - ‍COMPANY WILL COMMENCE AN EXECUTIVE SEARCH TO IDENTIFY A SUITABLE REPLACEMENT FOR CFO ROLE​.ATHENEX INC - ‍RIEHLE WILL CONTINUE TO SERVE AS AN ADVISOR TO COMPANY​.  Full Article

Athenex announces Q3 revenue of $14 million
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Athenex Inc :Athenex, Inc. Announces third quarter 2017 results.Q3 revenue rose 149 percent to $14 million.Sees FY 2017 revenue $33 million to $35 million.Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​.FY2017 revenue view $32.3 million -- Thomson Reuters I/B/E/S.Athenex Inc - Sees launch of 4 additional products in Athenex Pharmaceutical division & 2 products in Athenex Pharma solutions in 4Q'17​.  Full Article

Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program
Thursday, 5 Oct 2017 08:00am EDT 

Oct 5 (Reuters) - Athenex Inc :Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program.Athenex Inc - ‍DSMB encouraged rapid patient recruitment toward scheduled second interim analysis at 180 patients​.Athenex Inc - ‍DSMB unanimously recommended continuation of oraxol phase iii study​.Athenex Inc - ‍adverse event of painful neuropathy was "uncommon" with oraxol treatment​.Athenex Inc - expect clinical trial to proceed on track with rapid patient recruitment timelines & scheduled second interim analysis at 180 patients in 2018​.Athenex Inc - ‍expect trial to proceed on track with scheduled second interim analysis at 180 patients in 2018​.  Full Article

Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Athenex Inc :Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis.Athenex Inc - ‍Expects to complete recruitment of phase III studies within 8 months​.  Full Article

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER